Related Experiment Video
Updated: Jul 11, 2025
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.2K
[Pulmonary hypertension associated with lung disease]
Michael Halank1, Katarina E Zeder2,3, Natascha Sommer4,5
1Universitätsklinikum Carl Gustav Carus an der TU Dresden, Med. Klinik I, Bereich Pneumologie, Dresden, Deutschland.
Pneumologie (Stuttgart, Germany)
|November 14, 2023
Summary
Pulmonary hypertension (PH) often accompanies lung diseases, with severe cases indicating a poor prognosis. Prompt referral to PH clinics and individualized therapy are crucial for managing severe PH in lung disease patients.
Area of Science:
- Cardiology
- Pulmonology
- Internal Medicine
Context:
- Lung diseases and hypoventilation syndromes frequently present with pulmonary hypertension (PH).
- PH is hemodynamically defined by mean pulmonary arterial pressure (PAPm) >20 mmHg, pulmonary arterial wedge pressure (PAWP) ≤15 mmHg, and pulmonary vascular resistance (PVR) ≤5 Wood units (WU).
- Both non-severe (PVR ≤5 WU) and severe (PVR >5 WU) PH are associated with unfavorable prognoses.
Purpose:
- To outline diagnostic and therapeutic recommendations for PH associated with lung diseases.
- To identify risk factors for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
- To guide the management of severe PH in patients with COPD and interstitial lung disease.
Summary:
- Early identification of risk factors for PAH and CTEPH is recommended when PH is suspected.
- Patients with suspected severe PH or risk factors should be promptly referred to a PH outpatient clinic.
- Personalized therapy, including PH-specific drugs and inhaled treprostinil, should be considered for severe PH in lung disease patients, with specific criteria for COPD and interstitial lung disease.
Impact:
- Improved diagnostic pathways for PH in lung disease patients.
- Timely referral and intervention for patients with severe PH.
- Personalized treatment strategies to improve outcomes for patients with lung disease-related PH.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
194
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
194
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
233
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
233
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
01:17Other Pulmonary Disorders
853
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
853
01:29Pulmonary Embolism I: Introduction
7
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
7
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
163
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
163